{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:13:15Z","timestamp":1788775995129,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00415-026-14123-2","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:02:20Z","timestamp":1788775340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synaptic vesicle glycoprotein 2A PET imaging in parkinsonian \u03b1-synucleinopathies: a systematic review"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0873-4247","authenticated-orcid":false,"given":"Federico","family":"Garrou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Leva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Mauro","family":"Sacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Rosario","family":"De Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Tondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristoforo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"14123_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G et al (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14:176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"key":"14123_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49949-9","volume":"15","author":"A Zarkali","year":"2024","unstructured":"Zarkali A, Thomas GEC, Zetterberg H, Weil RS (2024) Neuroimaging and fluid biomarkers in Parkinson\u2019s disease in an era of targeted interventions. Nat Commun 15:5661. https:\/\/doi.org\/10.1038\/s41467-024-49949-9","journal-title":"Nat Commun"},{"key":"14123_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00823-x","volume":"10","author":"E Mantovani","year":"2024","unstructured":"Mantovani E, Martini A, Dinoto A et al (2024) Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses. npj Park Dis 10:211. https:\/\/doi.org\/10.1038\/s41531-024-00823-x","journal-title":"npj Park Dis"},{"key":"14123_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JPD-150642","volume":"5","author":"J Burr\u00e9","year":"2015","unstructured":"Burr\u00e9 J (2015) The synaptic function of \u03b1-synuclein. J Park Dis 5:699\u2013713. https:\/\/doi.org\/10.3233\/JPD-150642","journal-title":"J Park Dis"},{"key":"14123_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","volume":"46","author":"M Sharma","year":"2023","unstructured":"Sharma M, Burr\u00e9 J (2023) \u03b1-Synuclein in synaptic function and dysfunction. Trends Neurosci 46:153\u2013166. https:\/\/doi.org\/10.1016\/j.tins.2022.11.007","journal-title":"Trends Neurosci"},{"key":"14123_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126517","volume":"22","author":"A Cardinale","year":"2021","unstructured":"Cardinale A, Calabrese V, de Iure A, Picconi B (2021) Alpha-synuclein as a prominent actor in the inflammatory synaptopathy of Parkinson\u2019s disease. Int J Mol Sci 22:6517. https:\/\/doi.org\/10.3390\/ijms22126517","journal-title":"Int J Mol Sci"},{"key":"14123_CR7","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1007\/s00259-025-07695-0","volume":"53","author":"A Pees","year":"2026","unstructured":"Pees A, Grotegerd A-K, Bleher D et al (2026) PET imaging of alpha-synuclein: from radiotracer design through in vitro and in vivo translation. Eur J Nucl Med Mol Imaging 53:4211\u20134239. https:\/\/doi.org\/10.1007\/s00259-025-07695-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"14123_CR8","doi-asserted-by":"publisher","first-page":"60S","DOI":"10.2967\/jnumed.121.263201","volume":"63","author":"RE Carson","year":"2022","unstructured":"Carson RE, Naganawa M, Toyonaga T et al (2022) Imaging of synaptic density in neurodegenerative disorders. J Nucl Med 63:60S-67S. https:\/\/doi.org\/10.2967\/jnumed.121.263201","journal-title":"J Nucl Med"},{"key":"14123_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102197","volume":"94","author":"M Visser","year":"2024","unstructured":"Visser M, O\u2019Brien JT, Mak E (2024) In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: A systematic review. Ageing Res Rev 94:102197. https:\/\/doi.org\/10.1016\/j.arr.2024.102197","journal-title":"Ageing Res Rev"},{"key":"14123_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6667","volume":"8","author":"SJ Finnema","year":"2016","unstructured":"Finnema SJ, Nabulsi NB, Eid T et al (2016) Imaging synaptic density in the living human brain. Sci Transl Med 8:348ra96. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6667","journal-title":"Sci Transl Med"},{"key":"14123_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2967\/jnumed.120.249144","volume":"62","author":"M Naganawa","year":"2021","unstructured":"Naganawa M, Li S, Nabulsi N et al (2021) First-in-human evaluation of 18F-SynVesT-1, a radioligand for PET imaging of synaptic vesicle glycoprotein 2A. J Nucl Med 62:561\u2013567. https:\/\/doi.org\/10.2967\/jnumed.120.249144","journal-title":"J Nucl Med"},{"key":"14123_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"14123_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/emermed-2020-209567","volume":"37","author":"M Amir-Behghadami","year":"2020","unstructured":"Amir-Behghadami M, Janati A (2020) Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J 37:387. https:\/\/doi.org\/10.1136\/emermed-2020-209567","journal-title":"Emerg Med J"},{"key":"14123_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcag136","volume":"8","author":"S Cayir","year":"2026","unstructured":"Cayir S, Naganawa M, Volpi T et al (2026) Lower synaptic density in mood circuitry underlies depression in Parkinson\u2019s disease. Brain Commun 8:fcag136. https:\/\/doi.org\/10.1093\/braincomms\/fcag136","journal-title":"Brain Commun"},{"key":"14123_CR15","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ae520a","author":"P Gravel","year":"2026","unstructured":"Gravel P, Gallezot J-D, Fontaine K et al (2026) Variance reduction with synaptic density imaging in Parkinson\u2019s disease using direct-4D PET image reconstruction. Phys Med Biol. https:\/\/doi.org\/10.1088\/1361-6560\/ae520a","journal-title":"Phys Med Biol"},{"key":"14123_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41531-024-00655-9","volume":"10","author":"SE Holmes","year":"2024","unstructured":"Holmes SE, Honhar P, Tinaz S et al (2024) Synaptic loss and its association with symptom severity in Parkinson\u2019s disease. NPJ Park Dis 10:42. https:\/\/doi.org\/10.1038\/s41531-024-00655-9","journal-title":"NPJ Park Dis"},{"key":"14123_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X261441071","author":"N Khattar","year":"2026","unstructured":"Khattar N, Matuskey D, Gallezot J-D et al (2026) Optimized reference region and the effect on test\u2013retest reliability and sensitivity to differences between Parkinson\u2019s disease and control groups with [11C]UCB-J. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. https:\/\/doi.org\/10.1177\/0271678X261441071","journal-title":"J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab"},{"key":"14123_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2026.121853","author":"A Li","year":"2026","unstructured":"Li A, Naganawa M, Honhar P et al (2026) Dose reduction for synaptic density PET imaging in Parkinson\u2019s disease. Neuroimage. https:\/\/doi.org\/10.1016\/j.neuroimage.2026.121853","journal-title":"Neuroimage"},{"key":"14123_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ana.25682","volume":"87","author":"D Matuskey","year":"2020","unstructured":"Matuskey D, Tinaz S, Wilcox KC et al (2020) Synaptic changes in Parkinson disease assessed with in vivo imaging. Ann Neurol 87:329\u2013338. https:\/\/doi.org\/10.1002\/ana.25682","journal-title":"Ann Neurol"},{"key":"14123_CR20","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1002\/mds.70041","volume":"40","author":"FE Sadabad","year":"2025","unstructured":"Sadabad FE, Volpi T, Honhar P et al (2025) Measuring dopamine transporter availability and synaptic density in Parkinson\u2019s disease: a dual-tracer positron emission tomography imaging study. Mov Disord 40:2678\u20132687. https:\/\/doi.org\/10.1002\/mds.70041","journal-title":"Mov Disord"},{"key":"14123_CR21","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/mds.28617","volume":"36","author":"KB Andersen","year":"2021","unstructured":"Andersen KB, Hansen AK, Damholdt MF et al (2021) Reduced synaptic density in patients with Lewy body dementia: an [11 C]UCB-J PET imaging study. Mov Disord 36:2057\u20132065. https:\/\/doi.org\/10.1002\/mds.28617","journal-title":"Mov Disord"},{"key":"14123_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/mds.29375","volume":"38","author":"KB Andersen","year":"2023","unstructured":"Andersen KB, Hansen AK, Schacht AC et al (2023) Synaptic density and glucose consumption in patients with Lewy body diseases: an [11 C]UCB-J and [18 F]FDG PET study. Mov Disord 38:796\u2013805. https:\/\/doi.org\/10.1002\/mds.29375","journal-title":"Mov Disord"},{"key":"14123_CR23","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/mds.29148","volume":"37","author":"A Delva","year":"2022","unstructured":"Delva A, Van Laere K, Vandenberghe W (2022) Longitudinal positron emission tomography imaging of presynaptic terminals in early Parkinson\u2019s disease. Mov Disord 37:1883\u20131892. https:\/\/doi.org\/10.1002\/mds.29148","journal-title":"Mov Disord"},{"key":"14123_CR24","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/mds.28216","volume":"35","author":"A Delva","year":"2020","unstructured":"Delva A, Van Weehaeghe D, Koole M et al (2020) Loss of presynaptic terminal integrity in the substantia nigra in early Parkinson\u2019s disease. Mov Disord 35:1977\u20131986. https:\/\/doi.org\/10.1002\/mds.28216","journal-title":"Mov Disord"},{"key":"14123_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ana.27179","volume":"97","author":"J Li","year":"2025","unstructured":"Li J, Chen D, Tang Y et al (2025) Synaptic density reductions in MSA: a potential biomarker identified through [18F]SynVesT-1 PET imaging. Ann Neurol 97:879\u2013893. https:\/\/doi.org\/10.1002\/ana.27179","journal-title":"Ann Neurol"},{"key":"14123_CR26","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1007\/s00259-024-06993-3","volume":"52","author":"W Wang","year":"2025","unstructured":"Wang W, Wang Y, Xu L et al (2025) Presynaptic terminal integrity is associated with glucose metabolism in Parkinson\u2019s disease. Eur J Nucl Med Mol Imaging 52:1510\u20131519. https:\/\/doi.org\/10.1007\/s00259-024-06993-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"14123_CR27","doi-asserted-by":"publisher","first-page":"fcaf258","DOI":"10.1093\/braincomms\/fcaf258","volume":"7","author":"SL Martin","year":"2025","unstructured":"Martin SL, Uribe C, Desmond KL et al (2025) [18F]SynVest-1 PET imaging in people with Parkinson\u2019s disease. Brain Commun 7:fcaf258. https:\/\/doi.org\/10.1093\/braincomms\/fcaf258","journal-title":"Brain Commun"},{"key":"14123_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/1855985","author":"K Smart","year":"2023","unstructured":"Smart K, Uribe C, Desmond KL et al (2023) Preliminary assessment of reference region quantification and reduced scanning times for [18F]SynVesT-1 PET in Parkinson\u2019s disease. Mol Imaging. https:\/\/doi.org\/10.1155\/2023\/1855985","journal-title":"Mol Imaging"},{"key":"14123_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynirp.2026.100337","volume":"6","author":"JJ Schubert","year":"2026","unstructured":"Schubert JJ, Rota S, Batzu L et al (2026) Molecular neuroimaging of Parkinson\u2019s disease: association of motor and non-motor symptoms with synaptic density, dopaminergic and serotonergic systems. Neuroimage Rep 6:100337. https:\/\/doi.org\/10.1016\/j.ynirp.2026.100337","journal-title":"Neuroimage Rep"},{"key":"14123_CR30","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/mds.28064","volume":"35","author":"H Wilson","year":"2020","unstructured":"Wilson H, Pagano G, de Natale ER et al (2020) Mitochondrial complex 1, sigma 1, and synaptic vesicle 2A in early drug-naive Parkinson\u2019s disease. Mov Disord 35:1416\u20131427. https:\/\/doi.org\/10.1002\/mds.28064","journal-title":"Mov Disord"},{"key":"14123_CR31","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670\u2013676. https:\/\/doi.org\/10.1212\/01.wnl.0000324625.00404.15","journal-title":"Neurology"},{"key":"14123_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.796129","volume":"16","author":"ME Serrano","year":"2022","unstructured":"Serrano ME, Kim E, Petrinovic MM et al (2022) Imaging synaptic density: the next holy grail of neuroscience? Front Neurosci 16:796129. https:\/\/doi.org\/10.3389\/fnins.2022.796129","journal-title":"Front Neurosci"},{"key":"14123_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71283","volume":"22","author":"A Fesharaki-Zadeh","year":"2026","unstructured":"Fesharaki-Zadeh A, Cayir S, Ibrahim W et al (2026) Synaptic density imaging in behavioral variant frontotemporal dementia: a comparison of 1 8F-SynVesT-1 and 1 8F-FDG PET. Alzheimers Dement 22:e71283. https:\/\/doi.org\/10.1002\/alz.71283","journal-title":"Alzheimers Dement"},{"key":"14123_CR34","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1177\/0271678X211004312","volume":"41","author":"M-K Chen","year":"2021","unstructured":"Chen M-K, Mecca AP, Naganawa M et al (2021) Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer\u2019s disease: a tracer kinetic modeling study. J Cereb Blood Flow Metab 41:2395\u20132409. https:\/\/doi.org\/10.1177\/0271678X211004312","journal-title":"J Cereb Blood Flow Metab"},{"key":"14123_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.117877","volume":"232","author":"L Michiels","year":"2021","unstructured":"Michiels L, Delva A, van Aalst J et al (2021) Synaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study. Neuroimage 232:117877. https:\/\/doi.org\/10.1016\/j.neuroimage.2021.117877","journal-title":"Neuroimage"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14123-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14123-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14123-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:02:21Z","timestamp":1788775341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-14123-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14123"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14123-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a systematic review of previously published studies and does not contain new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors used QuillBot AI, version 41.27.1, for grammar and syntax correction and for limited paraphrasing of selected sentences. ChatGPT, GPT-5.5 Thinking, OpenAI, was used as a writing support tool in selected phases of manuscript preparation. All scientific content, interpretation, and final wording were reviewed and approved by the authors, who take full responsibility for the manuscript.","order":5,"name":"Ethics","label":"Declaration of generative AI use","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"570"}}